FDA: Factoring In Reimbursement, U.S. Bests Europe In Access To Innovative Devices
This article was originally published in The Gray Sheet
Executive Summary
FDA officials refute claims, frequently made by industry, that because FDA’s PMA review process is much slower than the CE mark regulatory process in Europe, Americans suffer delayed access to innovative and life-saving technology.